REXULTI | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
NEW Find Prospects
- Prospector
Drugs in Dev.
News
Blog
Market Place
Login

REXULTI
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

pharmacompass-1-m-2026-01-12

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

Contact Supplier

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Contact Supplier

pharmacompass-2-2026-02-09

REXULTI

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 21 USDMF, 6 EU WC, 3 KDMF, 10 NDC API, 41 Listed Suppliers, $ API Reference Price

51 API Suppliers
21 USDMF
6 EU WC
3 KDMF
10 NDC API
41 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

103 Drugs in Development

103 Drugs in Development

INTERMEDIATES

26 Intermediate Suppliers

26 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

151 FDF Dossiers, 96 FDA Orange Book, 33 Europe, 6 Canada, 5 Australia, 5 South Africa, 6 Listed Dossiers

151 FDF Dossiers
96 FDA Orange Book
33 Europe
6 Canada
5 Australia
5 South Africa
6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 0.25MG, TABLET;ORAL - 0.5MG, TABLET;ORAL - 1MG, TABLET;ORAL - 2MG, TABLET;ORAL - 3MG, TABLET;ORAL - 4MG

TABLET;ORAL - 0.25MG
TABLET;ORAL - 0.5MG
TABLET;ORAL - 1MG
TABLET;ORAL - 2MG
TABLET;ORAL - 3MG
TABLET;ORAL - 4MG

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 3 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 1 Aeon Procare, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 Corel Pharma Chem, 4 DFE Pharma, 5 Gangwal Chemicals, 4 Ideal Cures, 2 Ingredion Pharma Solutions, 19 Kerry, 1 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 15 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 2 Silverline Chemicals, 2 The Dow Chemical Company, 2 Vasa Pharmachem

4 SPI Pharma
3 Gangwal Healthcare
1 Nanjing Well Pharmaceutical
1 ACG Worldwide
1 Aeon Procare
5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
10 Corel Pharma Chem
4 DFE Pharma
5 Gangwal Chemicals
4 Ideal Cures
2 Ingredion Pharma Solutions
19 Kerry
1 Keval Exports
3 Kima Chemical
6 Lonza Capsugel
10 Microlex e.U
2 Nitika Pharmaceutical Specialities
1 Novo Excipients
1 Pharmatrans-Sanaq
3 Pluviaendo
2 Prachin Chemical
1 Qianhao Chemical (Hebei) Co., Ltd
1 Qualicaps
15 Roquette
7 Seppic
4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
9 Sigachi Industries
2 Silverline Chemicals
2 The Dow Chemical Company
2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

41 Fillers, Diluents & Binders, 37 Coating Systems & Additives, 17 Direct Compression, 15 Controlled & Modified Release, 14 Granulation, 11 Lubricants & Glidants, 10 Thickeners and Stabilizers, 10 Co-Processed Excipients, 9 Disintegrants & Superdisintegrants, 7 Taste Masking, 7 Chewable & Orodispersible Aids, 6 Film Formers & Plasticizers, 5 Empty Capsules, 4 Vegetarian Capsules, 3 API Stability Enhancers, 2 Coloring Agents, 2 Emulsifying Agents, 2 Rheology Modifiers, 1 Solubilizers, 1 Parenteral

41 Fillers, Diluents & Binders
37 Coating Systems & Additives
17 Direct Compression
15 Controlled & Modified Release
14 Granulation
11 Lubricants & Glidants
10 Thickeners and Stabilizers
10 Co-Processed Excipients
9 Disintegrants & Superdisintegrants
7 Taste Masking
7 Chewable & Orodispersible Aids
6 Film Formers & Plasticizers
5 Empty Capsules
4 Vegetarian Capsules
3 API Stability Enhancers
2 Coloring Agents
2 Emulsifying Agents
2 Rheology Modifiers
1 Solubilizers
1 Parenteral

DIGITAL CONTENT

1 Stock Recap #PipelineProspector, 62 News #PharmaBuzz

1 Stock Recap #PipelineProspector
62 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 18 Annual Reports

1 US Medicaid Prescriptions
18 Annual Reports

MARKET PLACE

12 APIs, 1 FDF Dossiers

12 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

88 US Patents, 30 US Exclusivities, 46 Health Canada Patents

88 US Patents
30 US Exclusivities
46 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 USP, 8 Others

2 USP
8 Others

$ API Ref.Price (USD/KG) : 10,615 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

46 All

01 11Smart & Biggar

02 35Smart & Biggar LLP

filter Patent Reset all filters

46 All

01 102602247

02 102832157

03 102851588

04 102870000

05 62889196

filter Product Reset all filters

46 All

01 46BREXPIPRAZOLE

filter Dosage Reset all filters

46 All

01 8KIT

02 38TABLET

filter Exp Date Reset all filters

46 All

01 102026-04-12

02 102032-04-04

03 102032-10-12

04 102033-04-23

05 62033-10-24

Polpharma Brexpiprazole

Product Main Page

01

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-04-12

Date Granted : 2013-04-02

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2602247

Filing Date : 2006-04-12

Strength per Unit : 0.25 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2026-04-12

Date Granted : 2013-04-02

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-04-23

Date Granted : 2021-02-16

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2870000

Filing Date : 2013-04-23

Strength per Unit : 0.25 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-04-23

Date Granted : 2021-02-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2832157

Filing Date : 2012-04-04

Strength per Unit : 0.25 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-10-24

Date Granted : 2021-02-16

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2889196

Filing Date : 2013-10-24

Strength per Unit : 0.25 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-10-24

Date Granted : 2021-02-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2832157

Filing Date : 2012-04-04

Strength per Unit : 0.5 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2832157

Filing Date : 2012-04-04

Strength per Unit : 1 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2832157

Filing Date : 2012-04-04

Strength per Unit : 2 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2832157

Filing Date : 2012-04-04

Strength per Unit : 3 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2832157

Filing Date : 2012-04-04

Strength per Unit : 4 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

Smart & Biggar

BREXPIPRAZOLE

ESF Europe

Not Confirmed

Smart & Biggar

Country

ESF Europe

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

BREXPIPRAZOLE

Brand Name : REXULTI

Patent Number : 2832157

Filing Date : 2012-04-04

Strength per Unit : 1mg / 2 mg

Dosage Form : KIT

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-04-04

Date Granted : 2023-06-27

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.